Decision analysis for resource allocation in health care

Journal of Health Services Research and Policy

Volumn 13, Issue SUPPL. 3, 2008, Pages 23-30

  Griffin, Susan ^a   Claxton, Karl ^a   Sculpher, Mark ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG INDUSTRY; ECONOMIC EVALUATION; ENVIRONMENT; FUNDING; HEALTH CARE; HEALTH CARE POLICY; HEALTH CARE SYSTEM; INFORMATION PROCESSING; INFORMATION SYSTEM; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; PARAMETER; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE PRICING; REIMBURSEMENT; RESEARCH PRIORITY; RESOURCE ALLOCATION; REVIEW; UNCERTAINTY; UNITED KINGDOM;

BAYES THEOREM; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; GREAT BRITAIN; HEALTH CARE RATIONING; UNCERTAINTY;

EID: 57349085048     PISSN: 13558196     EISSN: None     Source Type: Journal    
DOI: 10.1258/jhsrp.2008.008017     Document Type: Review

References (43)

1. Culyer AJ. The normative economics of health care finance and provision. Oxf Rev Econ Pol 1989;5:34-58
2. Tsuchiya A, Williams A. Welfare economics and economic evaluation. In: Drummond M, McGuire A, eds. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford University Press, 2001
3. Claxton K, Sculpher M, Culyer AJ. Mark versus Luke? Appropriate methods for the evaluation of public health interventions. Centre for Health Economics, University of York. CHE research paper 31, 2007
4. Sugden R, Williams A. The Principles of Practical Cost-Benefit Analysis. Oxford: Oxford University Press, 1979
5. Stinnett AA, Paltiel AD. Mathematical programming for the efficient allocation of health care resources. J Health Econ 1996;15:641
6. Epstein D, Chalabi Z, Claxton K, Sculpher M. Efficiency, equity and budgetary policies: informing decisions using mathematical programming. Med Decis Making 2007;27:128-37
7. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998;18 (Suppl. 2):S68-S80
8. Caldwell D, Ades AE, Higgins JPT. Simultaneous comparison ofmultiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900
9. Briggs AH, Sculpher MJ, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press, 2006
10. Luce B, O'Hagan A. A Primer on Bayesian Statistics in Health Economics and Outcomes Research. Bethesda, MD: Medtap International, 2003
11. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:342-64
12. Eckermann S, Willan A. Expected value of information and decision making in HTA. Health Econ 2006;16:195-209
13. Palmer S, Smith PC. Incorporating option values into the economic evaluation of health care technologies. J Health Econ 2000;19:755-66
14. Hutton J, Trueman P, Henshall C. Coverage with evidence development: an examination of conceptual and policy issues. Int J Technol Assess Health Care 2007;23:425-35
15. Griffin S, Claxton K, Palmer S, Sculpher M. Dangerous omissions: the consequences of ignoring decision uncertainty. Health Econ (in press)
16. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoecon 2000;17:479-500
17. McKay MD, Beckman RJ, Conover WJ. A comparison of three methods for selecting values of input variables in the analysis of output from a computer code. Technometrics 1979;21:239-45
18. Stevenson M, Oakley J, Chilcott J. Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis. Med Decis Making 2004;24:89-100
19. Tappenden P, Chilcott J, Eggington S, Oakley J, McCabe C. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis. Health Technol Assess 2004;8:1-78
20. Griffin S, Claxton K, Hawkins N, Sculpher M. Probabilistic analysis and computationally expensive models: necessary and required? Value Health 2006;9:244-52
21. Chaloner KM. Elicitation of prior distributions. In: Berry DA, Stangl DK, eds. Bayesian Biostatistics. New York, NY: Marcel Dekker, 1996:141-56
22. O'Hagan A, Buck CE, Daneshkhah A, et al. Uncertain Judgements: Eliciting Expert Probabilities. Chichester: Wiley, 2006
23. Hoeting JA, Madigan D, Raftery AE, Volinsky CT. Bayesian model averaging: A tutorial with discussion. Stat Sci 1999;14:382-417
24. Bojke L, Claxton K, Palmer S, Sculpher M. Defining and characterising structural uncertainty in decision analytic models. CHE research paper 9. 2006
25. Willan A, Briggs AH. Statistical Analysis of Cost-Effectiveness Data. Chichester: Wiley, 2006
26. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779- 89
27. Van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and c/e-ratios alongside a clinical trial. Health Econ 1994;3:309-19
28. Philips Z, Claxton K, Palmer S. The half-life of truth: appropriate time horizons for research decisions? Med Decis Making 2008;28:287-99
29. Chilcott J, Brennan A, Booth A, Karnon J, Tappenden P. The role of modelling in prioritising and planning clinical trials. Health Technol Assess 2003;7:1-125
30. Brennan A, Kharroubi S, O'Hagan A, Chilcott J. Calculating Partial Expected Value of Perfect Information via Monte Carlo Sampling Algorithms. Med Decis Making 2007;27:448-70
31. O'Hagan A, Stevenson M, Madan J. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: Efficient estimation of mean and variance using ANOVA. Health Econ 2007;16:1009-23
32. Brennan A, Kharroubi SA. Expected value of sample information for Weibull survival data. Health Econ 2007;16:1205-25
33. Cooksey D. A review of UK Health Research Funding. London: HM Treasury, 2006
34. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996;5:513-24
35. Willan AR, Pinto EM. The value of information and optimal clinical trial design. Stat Med 2005;24:1791-806
36. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for Authors of CCOHTA Health Technology Assessment Reports. Ottawa, ON: CCOHTA, 2003
37. NICE. Guide to the Methods of Technology Appraisal. London: National Institute for Health and Clinical Excellence, 2004
38. Pharmaceutical Management Agency Ltd (PHARMAC). A Prescription for Pharmacoeconomic Analysis. Report No.: Version 1.1. Wellington: Pharmaceutical Management Agency, 2004
39. Läkemedelsförmånsnämnden. The Pharmaceuticals Benefits Board - areas of responsibility and tasks. Contract No.: Document Number. Solna: LFN, 2004
40. An OFT market study. The pharmaceutical price regulation scheme. London: Office of Fair Trading, 2007
41. Claxton K, Briggs AH, Buxton MJ, et al. Value-based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008;336:251-4
42. Karnon J, Brennan A, Akehurst R. A critique and impact analysis of decision modelling assumptions. Med Decis Making 2007;27:491-9
43. Prevost TC, Abrams KR, Jones DR. Hierarchical models in generalized synthesis of evidence: an example based on studies of breast cancer screening. Stat Med 2000;19:3359-76